President Trump with Pfizer CEO Ian Read in July 2017 during an event to highlight a new American-made drug packaging product.

A new messaging tactic on the left: Drug prices rise, as pharma prospers from tax law

WASHINGTON — A tax policy group here is trying to rally outrage over last year’s Republican-backed tax cut by pointing to one of its main beneficiaries: the pharmaceutical industry.

Americans for Tax Fairness, a coalition of left-leaning groups that advocate for placing a heavier tax burden on corporations and the wealthy, said in a report that drug companies are “among the biggest winners from the Trump-GOP tax cuts, but they are sharing few of the benefits with their employees and are offering no pricing relief to their customers.”